Kornimate/medical-research-clean huggingface dataset:
evaluation of the the neuromodulation system for the treatment of overactive bladder symptoms

Conditions: Overactive Bladder

Summary: to evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical trial. the primary safety endpoint will be device-related adverse events. the primary effectiveness endpoint will be the improvement value of overactive bladder symptom score (oabss) after 12-week treatment.


Eligibility criteria:
inclusion criteria: 1. women and men aged between 18 and 80 years old (including 18 and 80 years old)； 2. individual with primary oab, or with oab symptoms, satisfies one of the following conditions: ① urinary urgency: sudden and strong desire to urinate, and it is difficult to be subjectively suppressed and delayed urination ; ② urge urinary incontinence: accompanied with urinary urgency or immediately after urinary urgency ; ③ urination frequency: adults urination frequency ≥8 times during the daytime，≥2 times at night, and each urine volume \<200 ml . 3. individual meets the diagnostic criteria of oab: according to the oabss questionnaire, urgency score ≥2 points, total score ≥3 points, and symptoms duration ≥3 months; 4. individual newly diagnosed with oab have not been medicated, or is able to stop taking oab-related drugs (m receptor block, β3 receptor agonists) for at least 2 weeks prior to enrollment; 5. the subject has autonomy and can go to the toilet independently; 6. individual is ambulatory and able to use the toilet independently; 7. individual is capable and willing to participate in the study and provide the written informed consent. exclusion criteria: 1. woman is pregnant or lactating, or woman of childbearing age who plans to become pregnant during the study period; 2. individual has stress urinary incontinence (sui); 3. individual has obvious urinary obstruction due to various reasons accompanied by residual urine volume\> 100 ml; 4. individual has an implanted pacemaker, embedded cardioverter defibrillator, or other electrical medical devices (including sacral neuromodulation (snm) devices) 5. individual has uncured urinary system infection; 6. individual has urinary calculus resulting in lower urinary tract symptoms; 7. individual has congenital urinary tract malformations causing uncured lower urinary tract symptoms; 8. individual has uncured cancers; 9. individual had undergone lower urinary tract surgery within 3 months; 10. individual has neurological diseases or injuries accompanied with uncured lower urinary tract symptoms; 11. individual has skin breakage, malignant tumor or acute purulent inflammation on the surface of the plantar where the electrode pads are to be placed; 12. individual has participated in other drug clinical trials medical dev within 3 months, or participated in other ice clinical trials within 30 days; 13. individual is deemed unsuitable for enrollment in the study by investigator.
xia shi surgical treatment for eczema multi-center clinical research

Conditions: Eczema

Summary: on the basis of xiashi skin surgery clinical experience, this project adopts the multicenter, randomized, double-blind, controlled trial of design type. objective, normative evaluation of traditional chinese medicine cool blood latent town effectiveness of therapeutic regimen in the treatment of eczema, security, and control of the relapse of situation, provide high-level evidence-based basis for traditional chinese medicine treatment of eczema, aims to form suitable for popularization and application of traditional chinese medicine in the treatment of eczema.


Eligibility criteria:
inclusion criteria: * accord with standard of syndrome differentiation of traditional chinese medicine (blood hot sheng) and western medicine diagnostic criteria (subacute eczema); * age between 18-65 years old, gender, ethnic unlimited; * agreed to participate in clinical trials can observe and cooperate with the visitor on schedule; * volunteered for this study and obtain informed consent will be; * lesion area of about 5-30% of surface area (bsa) were (containing 3% and 3%, palm measurement method) * iga scale of 1 to 3 points (including); * her lesions mainly located in the trunk and limbs (or); * women hcg negative; exclusion criteria: * known to the study of drug allergy to any of the components; * previous or current with any may affect the results of systemic disease, or other activity of skin diseases (such as: psoriasis); * has a liver and kidney function is not complete, liver damage of alt and ast \> 1.5 times the upper limit of normal, renal bun \> 1.5 times the upper limit of normal or creatinine \> 1.5 times the upper limit of normal value; * qtcb or qtcf acuity 450 milliseconds. for subjects qtc acuity bundle branch block 480 milliseconds. * prior or current with clinical significance of cardiovascular, lung disease, gastrointestinal tract, liver, kidney, blood, nerve abnormalities or mental disease; * breast-feeding or plan to pregnant women during test; * skin area score \> 30%; * eosinophil count score \> 10% * for nearly two weeks taking corticosteroids or a week, both inside and outside with corticosteroid preparation; * three months received study medication or other participated in other clinical subjects; * for any reason cannot cooperate research, for example: how language understanding, not to research centers, etc.; * researchers believe can bring obvious risk patients or confuse the results of the study, which should rule out other conditions or disease.

Keywords: xiashi surgical
guardant360® test-related clinical outcomes in patients who share medical records

Conditions: Non-Hematologic Malignancy

Summary: to document the clinical outcomes of cancer patients who received the guardant360® test and agree to share their records with guardant health.

this is an observational study of clinical outcomes to be conducted in the united states. patients with a diagnosis of stage 3-4 advanced cancer who possess specific pathway mutations identified by the guardant360® test will be eligible to enroll in the study. patients will be recruited by telephone or email and/or through the guardant health patient portal to determine interest in the study. should patients be interested in contributing to this registry study, they will be prompted to consent via a commercial service for patients to request, manage, and view their medical records. enrolled participants will be requested to release copies of their medical records for review by the principal investigator. study adminsitrators will abstract participant demographics, cancer-related therapies, and clinical outcomes for analysis.

Eligibility criteria:
general inclusion criteria: * adults (≥ 18 years old) with a diagnosis of stage 3 or stage 4 cancer (non-hematologic malignancy). patients with advanced cancers not typically staged 1-4 (such as extensive stage small lung cancer) may be enrolled. * results from guardant360® test * patient has previously provided contact information (either email or phone) to guardant health. * able and wiling to complete the informed consent process. * willingness to consent to the release of medical records. * willingness to provide medical records release general exclusion criteria: * unwilling or unable to provide written informed consent. * unable to understand english. * diagnosis of nsclc * guardant 360® test results released to the patient's physician no less than 14 days and no greater than 60 days prior to initial patient contact.

Keywords: guardant health greco
pc-trial: patent foramen ovale and cryptogenic embolism

Conditions: Embolism, Paradoxical; Heart Septal Defects, Atrial

Summary: the purpose of this study is to compare two treatments strategies to prevent further attacks in patients who have suffered an stroke or occlusion of a major artery with no obvious reason other than a persistent small opening between the upper heart chambers

in patients who have suffered a stroke or occlusion of a large artery in another body part of unknown origin a possible cause is a small opening between the upper heart chambers (patent foramen ovale, it is called). after birth this opening closes in 75% of the population, while it persists in 25% of people. it may allow a small blood clot to pass from the veins of the legs through the heart into the brain or other parts of the body. in order to reduce the risk for a further attack we have today more therapeutic options to choose from but it is unclear which strategy have the best outcome. this study is created to compare the effect of two treatment strategies: 1. medical treatment the purpose of medical treatment is to dilute the blood to a degree, that no thrombus formation occurs. since the opening in the heart persists, treatment is usually recommended lifelong. and patients treated with coumadin must undergo regular blood tests to ensure an adequate effect of the drug. 2. catheter closure of patent foramen ovale an alternative method developed to close the small opening in the heart utilizes catheters which are introduced in a blood vessel in the groin and from there advanced to the heart. an umbrella device is then delivered through the catheter, positioned within the small defect and released. the umbrella is overgrown with own tissue within weeks to months and closes the small defect for ever.

Eligibility criteria:
inclusion criteria: * age below 60 years * ischemic stroke or peripheral thromboembolism, radiologically verified * absence of an identifiable cause of embolism * echocardiographically verified patent foramen ovale * sufficient recovery from index event to allow independent daily activities exclusion criteria: * any identifiable cause for thromboembolic event other than pfo * cardiac diseases: mural thrombus, dilated cardiomyopathy, prosthetic heart valve or mitral stenosis, endocarditis, atrial fibrillation * vascular system: significant atherosclerosis or dissection of the aorta, collagen vascular disease, arteritis, vasculitis * pre-existing neurologic disorders or intracranial disease, e.g., multiple sclerosis, arteriovenous malformations, previous hemorrhage * contraindications for antithrombotic or anticoagulant therapy * patients already on chronic anticoagulant therapy for another disease * previous surgical or percutaneous pfo-closure * drug or alcohol abuse * pregnancy * septicemia or severe infectious disease * severe cns disease * no informed consent * foreseen difficulties with study compliance, especially the long-term follow-up

Keywords: paradoxical embolism, patent foramen ovale,
drug-drug interaction and food-effect study with glpg4716 and midazolam in healthy subjects

Conditions: Healthy

Summary: the purpose of this study is to determine the effect of the administration of multiple doses of glpg4716 on the amount of midazolam (mdz) that gets into the blood when the two drugs are administered together compared to when midazolam is administered alone. other objectives of this study are to evaluate the safety and tolerability of glpg4716 when administered with midazolam and assess the amount of glpg4716 that gets into the blood when administered with midazolam. this study will also assess the effect of food on the amount of glpg4716 that gets into the blood.


Eligibility criteria:
inclusion criteria: * male or female between 18 and 55 years of age (extremes included), on the date of signing the informed consent form. female subjects should be of non-childbearing potential. * a body mass index between 18.0 and 30.0 kg/m2, inclusive. * judged to be in good health by the investigator based upon: * the results of a medical history * physical examination * vital signs * oxygen saturation * 12-lead electrocardiogram * fasting clinical laboratory safety tests. aspartate aminotransferase and alanine aminotransferase must be no greater than 1.5x upper limit of normal range and total bilirubin no greater than 1x upper limit of normal. other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator. this list only contains the key inclusion criteria. exclusion criteria: * known hypersensitivity to ingredients of glpg4716 and/or mdz * history of a significant allergic reaction to ingredients of glpg4716 and/or mdz as determined by the investigator. * treatment with any medication including: * over-the-counter and/or prescription medication * dietary supplements * nutraceuticals, vitamins and/or herbal supplements, and hormonal replacement therapy * except occasional paracetamol (maximum dose of 2 g/day and maximum of 10 g/2 weeks) in the last 2 weeks or 5 half-lives of the drug, whichever is longer, prior to the first dosing. this list only contains the key exclusion criteria.
fontan circulation and cardiopulmonary function: prognostic factors, hemodynamics and long-term effects

Conditions: Congenital Heart Disease

Summary: cross-sectional study of a national cohort of adolescents with univentricular congenital heart defects and fontan type palliation.

a study group of 40-50 individuals will be investigated by non-invasive and invasive methods, including echocardiography at rest and during exercise, heart catheterization with advanced hemodynamic studies, cardiac and abdominal mri, abdominal ultrasound and transient elastography, quality of life assessment and cardiopulmonary exercise testing. a selection of tests will be performed in a healthy control group as well.

Eligibility criteria:
inclusion criteria: * age, heart defect, heart surgery and type of palliation/correction, informed consent exclusion criteria: * non-consenting, contraindications or increased risk to perform study tests (i.e. metal parts prohibiting mri, motoric impairment prohibiting cpet)

Keywords: univentricular heart defect fontan circulation
study evaluating rfix; benefix in severe hemophilia b

Conditions: Hemophilia B

Summary: to characterize the safety and efficacy of rfix in children less than 6 years of age with severe hemophilia b in the setting of acute bleeding episodes, prophylaxis, and/or surgery. this study will provide an opportunity for systematic observation of treatment with rfix in children less than 6 years of age regardless of prior fix treatment. younger patients exhibit a different pharmacokinetic profile and therefore may respond differently to rfix infusions when compared with older children and adults. this evaluation will provide data from which recommendations can be made regarding rfix dosing and treatment of these patients. surveillance for certain observations that have been made in patients treated with rfix in the clinical and postmarketing setting will be performed, including inhibitor development, thrombogenicity, fix recovery/lack of effect, allergic-type manifestations, and rbc agglutination. comparisons will be derived from published reports and communications describing experience with other fix products and protein therapeutics in general.


Eligibility criteria:
inclusion criteria: * severe hemophilia b * less than 5 years of age * in the investigator's judgment, the patient and/or caregiver will be compliant to study procedures exclusion criteria: * a currently detectable fix inhibitor. a family history of inhibitors will not exclude the patient. * impaired liver function * impaired renal function

Keywords: hemophilia b
quadriceps motor unit adaptation to simulated knee injury

Conditions: Muscle Inhibition; Knee Injury Simulation

Summary: this study investigates how simulated knee injury-via artificial joint effusion or deafferentation-affects quadriceps motor unit behavior in healthy young adults. participants will complete neuromuscular testing during a single 2-hour lab session. this research seeks to improve understanding of muscle inhibition and inform interventions after real-world knee trauma.

using a controlled laboratory model, the investigators will simulate knee injury through two methods: (1) intra-articular saline injection to induce effusion, and (2) intra-articular lidocaine injection to induce sensory deafferentation. healthy participants aged 18-30 will undergo surface and decomposition emg, isometric strength testing, and reflex measurements before and after the intervention. the primary outcome is motor unit recruitment characteristics, with secondary outcomes including quadriceps inhibition (hoffmann reflex) and isometric peak torque. the findings will inform future neuromodulatory approaches in rehabilitation.

Eligibility criteria:
inclusion criteria: 1. age 18-30 years 2. physically active (tegner ≥ 5) 3. no prior lower-limb surgery or major injury exclusion criteria: 1. lower limb surgery or significant injury in past 2 years 2. cardiopulmonary, neurological, or psychiatric disorders 3. needle/electrical stimulation anxiety 4. medications affecting neuromuscular or psychological function 5. pregnancy 6. allergic to lidocaine 7. inability to elicit hoffmann reflex

Keywords: quadriceps electromyography motor unit knee effusion lidocaine deafferentation neuromuscular adaptation muscle strength
safety study of transumbilical single incision versus conventional laparoscopic surgery for colorectal cancer

Conditions: Colorectal Cancer

Summary: * compared with traditional open colectomy, laparoscopic surgery is associated with less pain, earlier recovery, and better cosmetic outcome, and its short- and long-term oncologic outcomes have been demonstrated. * in experienced surgeons' hands, single incision laparoscopic surgery is increasingly performed for colorectal disease, and even for malignant lesion because of its reduced incision-associated morbidity and scarring. * however, the safety and efficacy of single incision laparoscopic surgery for colorectal cancer has not yet been evaluated. thus, the prospective randomized trial comparing single incision versus conventional laparoscopic surgery for colorectal cancer is needed.


Eligibility criteria:
inclusion criteria: * 18 years \< age \< 80 years * tumor located in rectosigmoid (defined as 10- to 30-cm from the anal verge) * pathological rectosigmoid carcinoma * preoperative t stage ranging from t1 to t4a according to the 7th edition of ajcc cancer staging manual * tumor size of 5 cm or less; 6) ecog score is 0-1 * asa socre is ⅰ-ⅲ * informed consent exclusion criteria: * body mass index (bmi) \>30 kg/m2 * pregnant woman or lactating woman * severe mental disease * previous abdominal surgery * emergency operation due to complication (bleeding, perforation or obstruction) caused by colorectal cancer * requirement of simultaneous surgery for other disease

Keywords: single-incision laparoscopy colorectal cancer
burn outcomes in young adult burn survivors

Conditions: Burns; Trauma

Summary: as part of clinical trials.gov id:nct00253292 a psychometrically sound outcomes instrument was developed to study the outcomes of burn survivors in the 19-30 year old age group. this workgroup has come together to re-examine the data collected during the previous study and determine next steps in understanding the recovery for this population.

this study looks to understand previously collected outcomes scores. identifying young adult burned patients at risk for poor outcomes remains an under-published field of study. we strive to identify problem areas for this population before they adversely effect their quality of life. how are these 19-30 year olds different from their non-burned counterparts and what interventions can we provide to equalize the balance?

Eligibility criteria:
inclusion criteria: all burn injured young adults with or without skin grafting. all burned young adults on or after their 18th birthday. between the ages of 19-30 years. english speaking present for inpatient or outpatient treatment. - exclusion criteria: non-burn skin conditions. non-english speaking young adults. young adults less than 19 years of age. young adults greater than 30 years of age. -

Keywords: burns trauma outcomes quality of life
effect of adding isoflavonoids to clomiphene citrate for ovulation induction in women with polycystic ovary syndrome

Conditions: Ovulation Induction; Polycystic Ovary Syndrome

Summary: this prospective, randomized clinical trial double blinded study, has been carried on 160 infertile patients seeking pregnancy in gynecology and obstetrics department, zagazig university hospitals during the period from january 2019 to november 2019, the participants' randomizations were done and patients divided into two groups; group i: included 80 women receiving clomiphene citrate (cc) plus isoflavonoids. group 2: included 80 women receiving clomiphene citrate only

phytoestrogens continue to be of increasing interest because of their possible influence on the physiology of the reproductive tract. the aim of prospective randomized clinical trial study is to evaluate effect of adding isoflavonoids to clomiphene citrate during ovulation induction in women with pcos on the endometrial thickness which has an impact on pregnancy rate. this study included 160 infertile women seeking pregnancy and they were divided into two groups. clomiphene is given orally at dose, one tablet twice per day (tablet 50 mg), from day 3 to day 7 for all patients (group i and group ii),while phytoestrogens are given at dose, two tablets two times per day (tablet 800mg), from day 3 to day 12 only for group i, followed by hcg injection on attaining mature follicle(s) by trans-vaginal us scan with diameter ≥ 18 mm.

Eligibility criteria:
inclusion criteria: • patient aged 18- 35 years old with primary or secondary infertility exclusion criteria: * patient aged 18- 35 years old with primary or secondary infertility * patient whose husband has a male factor of infertility. * hepatic, renal, diabetic, thyroid or cardiovascular disorders. * organic pelvic disease (uterine fibroids or ovarian cysts). * abnormality detected by hsg as blocked tubes

Keywords: human chorionic gonadotropin clomiphene citrate isoflavonoids polycystic ovary syndrome